A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL (waveLINE)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501380-40-00

Acronym

MK-2140-007

Enrollment

Registered

2023-03-17

Start date

2022-08-10

Completion date

Unknown

Last updated

2025-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma (DLBCL)

Brief summary

Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) in Cycle 1, Number of Participants Who Experienced At Least One Adverse Event (AE), Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE), Complete Response Rate (CRR) per Lugano Response Criteria

Detailed description

Objective Response Rate (ORR) per Lugano Response Criteria, Duration of Response (DOR) per Lugano Response Criteria

Interventions

DRUG-

DRUGPREDNISOLONE

DRUGRITUXIMAB

DRUGPREDNISONE

DRUGDOXORUBICIN

DRUGZilovertamab vedotin

DRUGCYCLOPHOSPHAMIDE

DRUGTruxima 500 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) in Cycle 1, Number of Participants Who Experienced At Least One Adverse Event (AE), Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE), Complete Response Rate (CRR) per Lugano Response Criteria	—

Secondary

Measure	Time frame
Objective Response Rate (ORR) per Lugano Response Criteria, Duration of Response (DOR) per Lugano Response Criteria	—

Countries

Italy, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026